Drug Profile
Autologous Epstein-Barr virus-specific T-cell therapy - bluebird bio/University College London
Alternative Names: Autologous EBV-CTL - bluebird; Autologous Epstein-Barr virus-specific T-cell therapy - bluebird bio/University College London; EBV-CTL - bluebird/University College London; EBV-specific T-cells - bluebird bio/University College London; Epstein-Barr virus specific cytotoxic T-lymphocytes - bluebird bio/University College London; Tacrolimus resistant EBV-CTL -bluebird; Tacrolimus-resistant autologous Epstein-Barr virus-specific T-cell therapy - bluebirdLatest Information Update: 28 May 2021
Price :
$50
*
At a glance
- Originator bluebird bio; University College London
- Class Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Post-transplant lymphoproliferative disorder
Most Recent Events
- 28 May 2021 No recent reports of development identified for preclinical development in EBV-associated B-cell hyperplasia in renal transplant recipients in United Kingdom (IV)
- 24 Apr 2017 Preclinical trials in Post-transplant lymphoproliferative disorder in United Kingdom prior to April 2017 (IV)
- 24 Apr 2017 bluebird bio in collaboration with University College London plans a phase I trial for Post-transplant lymphoproliferative disorder (In infants; In children; In adolescents; In adults; In the elderly) in United Kingdom (NCT03131934)